Bevacizumab-Induced Vessel Normalization Hampers Tumor Uptake of Antibodies--Response (original) (raw)
Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
Alessandro Ottaiano
Frontiers in Oncology, 2021
View PDFchevron_right
Early Antivascular Effects of Bevacizumab Anti-VEGF Monoclonal Antibody on Colorectal Carcinomas Assessed With Functional CT Imaging
George Kouklakis
American Journal of Clinical Oncology, 2007
View PDFchevron_right
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
Oliver Coutelle
British Journal of Cancer, 2017
View PDFchevron_right
Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma
Julian Rey
NMR in Biomedicine, 2021
View PDFchevron_right
Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts
Bishnuhari Paudyal
Cancer Science, 2011
View PDFchevron_right
Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
Helmut Maecke
The Journal of Nuclear Medicine, 2014
View PDFchevron_right
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.pdf
Giorgio Seano
View PDFchevron_right
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Jeffrey Clark
Nature Medicine, 2004
View PDFchevron_right
Does Imaging v 3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
S. Rylova, Helmut Maecke
Journal of Nuclear Medicine, 2014
View PDFchevron_right
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach
Otto Boerman, Hanneke Van Laarhoven
Investigational New Drugs, 2013
View PDFchevron_right
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
fabrizio vianello
Proceedings of the National Academy of Sciences, 2012
View PDFchevron_right
Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response
enrico davoli
Molecular cancer therapeutics, 2015
View PDFchevron_right
Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with ^ Cu-labeled bevacizumab in colorectal cancer xenografts
Bishnuhari Paudyal
Cancer Science, 2011
View PDFchevron_right
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
Hans-peter Gerber
Cancer research, 2005
View PDFchevron_right
Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
Melpomeni Fani
Journal of Nuclear Medicine, 2014
View PDFchevron_right
Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth
Jane de Moraes
Cancer science, 2016
View PDFchevron_right
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment
Sjoukje Oosting, Adrienne Brouwers
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015
View PDFchevron_right
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
Napoleone Ferrara
Clinical Cancer Research, 2009
View PDFchevron_right
Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells
Yvonne Kienast
Clinical Cancer Research, 2011
View PDFchevron_right
Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study
Hans-heinrich Wolf
Bone Marrow Transplantation, 2010
View PDFchevron_right
Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression
A. Geurts-Moespot
Molecular pharmaceutics, 2014
View PDFchevron_right
Data from Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response
enrico davoli
2023
View PDFchevron_right
Preclinical evaluation of (131)I-Bevacizumab - A prospective agent for radioimmunotherapy in VEGF expressing cancers
Haladhar Dev Sarma
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2017
View PDFchevron_right
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
Egbert Oosterwijk
Journal of Nuclear Medicine, 2010
View PDFchevron_right
Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer
Jose Juan Illarramendi Mañas
Cancers, 2021
View PDFchevron_right
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Pieter E Postmus
Cancer Cell, 2012
View PDFchevron_right
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients
Michele Caraglia
Cancer Biology & Therapy, 2010
View PDFchevron_right
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model
E. ter Voert
Contrast Media & Molecular Imaging, 2014
View PDFchevron_right
Noninvasive Contrast-enhanced US Quantitative Assessment of Tumor Microcirculation in a Murine Model: Effect of Discontinuing Anti-VEGF Therapy
Delphine Le Guillou-buffello
Radiology, 2010
View PDFchevron_right